Zoetis [ZTS] vs Regencell Bioscience [RGC] Detailed Stock Comparison

Zoetis Inc.

NYSE
Loading...

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Zoetis Inc. wins in 12 metrics, Regencell Bioscience Holdings Ltd. wins in 3 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Zoetis Inc. Regencell Bioscience Holdings Ltd. Better
P/E Ratio (TTM) 19.58 -3,258.62 Zoetis Inc.
Price-to-Book Ratio 15.04 2,929.00 Zoetis Inc.
Debt-to-Equity Ratio 279.59 11.20 Regencell Bioscience Holdings Ltd.
PEG Ratio 2.81 N/A N/A
EV/EBITDA 13.96 -3,921.47 Zoetis Inc.
Profit Margin (TTM) 28.24% 0.00% Zoetis Inc.
Operating Margin (TTM) 34.69% 0.00% Zoetis Inc.
EBITDA Margin (TTM) 34.69% N/A N/A
Return on Equity 65.99% -54.81% Zoetis Inc.
Return on Assets (TTM) 15.26% -33.20% Zoetis Inc.
Free Cash Flow (TTM) $2.28B $-4.01M Zoetis Inc.
Dividend Yield 1.21% N/A N/A
1-Year Return -51.58% 20.24% Regencell Bioscience Holdings Ltd.
Price-to-Sales Ratio (TTM) 5.26 N/A N/A
Enterprise Value $56.75B $14.48B Zoetis Inc.
EV/Revenue Ratio 6.00 N/A N/A
Gross Profit Margin (TTM) 70.17% N/A N/A
Revenue per Share (TTM) $21 $0 Zoetis Inc.
Earnings per Share (Diluted) $6.02 $-0.01 Zoetis Inc.
Beta (Stock Volatility) 0.97 2.25 Zoetis Inc.
Short % of Float 4.06% 1.26% Regencell Bioscience Holdings Ltd.

Zoetis Inc. vs Regencell Bioscience Holdings Ltd. Stock Performance Analysis

Loading Price Chart...

ZTS
RGC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%
Regencell Bioscience Holdings Ltd.-9.24%-20.10%-40.20%-24.65%-0.98%-16.80%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%
Regencell Bioscience Holdings Ltd.20.24%2,888.89%6,625.00%6,625.00%6,625.00%6,625.00%

Performance & Financial Health Analysis: Zoetis Inc. vs Regencell Bioscience Holdings Ltd.

MetricZTSRGC
Market Information
Market Cap i$49.75B$14.00B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,727,710105,478
90 Day Avg. Volume i3,835,940162,743
Last Close$167.10$17.09
52 Week Range$139.70 - $200.33$9.39 - $83.60
% from 52W High-16.59%-79.56%
All-Time High$249.27 (Dec 27, 2021)$950.00 (May 30, 2025)
% from All-Time High-32.96%-98.20%
Growth Metrics
Quarterly Revenue Growth0.03%N/A
Quarterly Earnings Growth0.04%N/A
Financial Health
Profit Margin (TTM) i0.28%0.00%
Operating Margin (TTM) i0.35%0.00%
Return on Equity (TTM) i0.66%-0.55%
Debt to Equity (MRQ) i279.5911.20
Cash & Liquidity
Book Value per Share (MRQ)$7.84$0.01
Cash per Share (MRQ)$5.48$0.01
Operating Cash Flow (TTM) i$2.90B$-3,113,576
Levered Free Cash Flow (TTM) i$1.79B$-1,507,277
Dividends
Last 12-Month Dividend Yield i1.21%N/A
Last 12-Month Dividend i$2.03N/A

Valuation & Enterprise Metrics Analysis: Zoetis Inc. vs Regencell Bioscience Holdings Ltd.

MetricZTS (Apr 13, 2026)RGC (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.58-3,258.62
Forward P/E i15.61N/A
PEG Ratio i2.81N/A
Price to Sales (TTM) i5.26N/A
Price to Book (MRQ) i15.042,929.00
Market Capitalization
Market Capitalization i$49.75B$14.00B
Enterprise Value i$56.75B$14.48B
Enterprise Value Metrics
Enterprise to Revenue i6.00N/A
Enterprise to EBITDA i13.96-3,921.47
Risk & Other Metrics
Beta i0.972.25
Book Value per Share (MRQ) i$7.84$0.01

Financial Statements Comparison: Zoetis Inc. vs Regencell Bioscience Holdings Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricZTS (2025)RGC (2024)
Revenue/Sales i9.47B0
Cost of Goods Sold i2.67BN/A
COGS % of Revenue i28.2%-
Gross Profit i6.80BN/A
Gross Margin i71.8%-
Research & Development i698.00M1.07M
Operating Income (EBIT) i3.60B-4.74M
Operating Margin i38.0%-
EBITDA i4.17B-3.99M
EBITDA Margin i44.1%-
Pre-Tax Income i3.36B-4.36M
Pre-Tax Income % of Revenue i35.5%-
Income Tax i687.00M0
Income Tax % of Revenue i7.3%-
Net Income (Profit) i2.67B-4.36M
Profit Margin i28.2%-

Balance Sheet & Liquidity Metrics

MetricZTS (2025)RGC (2024)
Cash & Equivalents i2.31B2.96M
Total Current Assets i6.77B8.11M
Total Current Assets % of Revenue i71.5%-
Total Current Liabilities i2.24B193,578
Total Current Liabilities % of Revenue i23.6%-
Long-Term Debt i9.24B25,934
Long-Term Debt % of Revenue i97.6%-
Total Shareholders Equity i3.33B8.22M
Retained Earnings i13.74B-21.62M
Retained Earnings % of Revenue i145.2%-
Property, Plant & Equipment i288.00M84,780

Cash Flow Statement Comparison

MetricZTS (2025)RGC (2024)
Operating Cash Flow i2.78B-3.88M
Operating Cash Flow % of Revenue i29.3%-
Capital Expenditures iN/A-5,376
Free Cash Flow i2.28B-4.01M
FCF Margin i24.1%-
Debt Repayment i-1.35BN/A
Common Stock Repurchase i-3.24BN/A

Short Interest & Institutional Ownership Analysis

MetricZTSRGC
Shares Short i15.12M700,509
Short Ratio i3.605.62
Short % of Float i4.06%1.26%
Shares Outstanding i424.93M494.49M
Float Shares i421.29M43.94M
% Held by Insiders i0.15%88.56%
% Held by Institutions i101.50%0.12%
% Held by Public i-1.65%11.32%

Dividend Analysis & Yield Comparison: Zoetis Inc. vs Regencell Bioscience Holdings Ltd.

MetricZTSRGC
Last 12-Month Dividend i$2.03N/A
Last 12-Month Dividend Yield i1.21%N/A
3-Year Avg Annual Dividend i$1.80N/A
3-Year Avg Dividend Yield i0.29%N/A
3-Year Total Dividends i$5.39N/A
Ex-Dividend DateJan 20, 2026N/A